Chief Medical Officer (7) · Immunovant, Inc. (IMVT)

William Macias

A named executive officer of Immunovant in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,918,906

Salary $500,000Stock awards $562,952Bonus $210,000

FY2022: $6,823,389

3rd of 3 named executive officers at Immunovant by FY2023 total.

3 named officers on file for Immunovant, FY2023

William Macias’s pay file — $29

  • 2 fiscal years of pay, line by line
  • IMVT’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Immunovant’s whole pay program stands against its peers

  • Immunovant’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IMVT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 26, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get William Macias’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

William Macias compensation by year

Immunovant Summary Compensation Table · all 2 fiscal years held
In US dollars, as Immunovant reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$98,686$500,000
Bonus$94,630$210,000
Stock awards$961,887$562,952
Option awards$1,142,334$636,078
Non-equity incentive$0—
Pension and deferred compensation$0$0
All other$4,525,852$9,876
Total$6,823,389$1,918,906

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Immunovant, Inc. DEF 14A filed June 26, 2023, accession 0001764013-23-000072, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Immunovant, Inc. filed document, accession 0001764013-23-000072. Every figure is read from that document and cited to the page and table it appears in. Filed June 26, 2023.

$6.8M
$1.9M
FY22
FY23
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU112,816$1,749,776—
RSU10,505$162,933—
Option169,648—$4.99
Option207,743—$10.71
Option115,036—$8.58

Per the Outstanding Equity Awards at Fiscal Year-End table in Immunovant, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

29 Form 4 lines since the FY2023 proxy (filed June 26, 2023)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-02-19Sale—2,055$20.86357,353
2025-01-15Sale—94$24.19359,814
2025-01-15Sale—387$23.81359,427
2025-01-15Sale—19$24.19359,408
2025-01-15Sale—1,883$23.81359,908
2024-11-20Sale—3,353$25.45361,791
2024-10-16Sale—2,627$28.79365,705
2024-10-16Sale—561$28.79365,144

The 8 most recent of 29 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Immunovant’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Peter SalzmannChief Executive Officer$5,819,818
Eva Renee BarnettChief Financial Officer (4)$2,070,095
William Macias · this pageChief Medical Officer (7)$1,918,906

The full Immunovant compensation record

free company brief

This page is one person within Immunovant's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Immunovant proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Immunovant's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

William Macias's compensation dossier · One-time report. No refunds.